MDACC Study No:2012-0543 ( NCT No: NCT01797523)
Title:A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients with Advanced or Recurrent Endometrial Carcinoma
Principal Investigator:Pamela Soliman
Treatment Agent:Letrozole; Metformin; RAD001
Study Status:Open
Study Description:The goal of this clinical research study is to learn if the combination of
everolimus, letrozole, and metformin can help to control recurrent or
progressive endometrial cancer. The safety of this drug combination will also
be studied.

Everolimus is designed to block a protein inside cancer cells that is involved
in cancer growth.

Letrozole is designed to block a protein from making estrogen. This may
interfere with the growth of cancer cells.

Metformin is commonly used to control blood sugar levels in patients with
diabetes. It is designed to lower insulin levels, which may slow or stop the
growth of endometrial cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Gynecology
Phase of Study:Phase II
Treatment Agents:Letrozole
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Novartis
SPORE Grant (Matching)
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Pamela Soliman
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-745-2352
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults